RISPERDAL News
Most Popular RISPERDAL Story
ALSO NOTED: FDA rejects Risperdal for Alzheimer's; Elan CEO bullish on Tysabri's return; Myogen, Novartis expand pact; and much
> Johnson & Johnson says the FDA has turned thumb's down on Risperdal as a treatment of psychosis in Alzheimer's. Read more...
Latest Headlines
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




